|Tel||+44 (0)1865 289422|
- Conducting economic evaluations of perinatal interventions from a family perspective: identification of challenges for analyses and exploration of potential solutions Research Group
- Mapping algorithms from non-preference to preference-based outcome measures: do they really work in practice? Research Group
- Conducting economic evaluations of perinatal interventions from a family perspective Research Group
Helen Dakin joined the Health Economics Research Centre in February 2008. Before starting at HERC, she worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She previously graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials.
Her current projects include: the STAR trial, which evaluates radiotherapy alongside bevacizumab (Avastin) in age-related macular degeneration; the ACHE study, which evaluates clinical tools and thresholds for selecting patients for joint replacement; and the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component.
Research paper on factors influencing NICE decisions available here.
Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L.
Dixon P. et al, (2016), Qual Life Res, 25, 935 - 945
Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement.
Petrou S. et al, (2016), Qual Life Res, 25, 275 - 281
The Maps Reporting Statement for Studies Mapping onto Generic Preference-Based outcome Measures.
Petrou S. et al, (2015), Value Health, 18, A715 - A716
The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.
Petrou S. et al, (2015), Pharmacoeconomics, 33, 993 - 1011
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement.
Petrou S. et al, (2015), Pharmacoeconomics, 33, 985 - 991